Cencora (NYSE:COR) Shares Gap Down – Should You Sell?

Cencora, Inc. (NYSE:COR) gapped down before the market opened on Wednesday . The stock had previously closed at $333.87, but opened at $319.59. Cencora shares last traded at $321.3230, with a volume of 178,179 shares.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Wells Fargo raised its price target on Cencora from $331 to $395 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Benzinga report
• Positive Sentiment: Brokerage coverage remains generally favorable, with Cencora receiving an average “Moderate Buy” rating and a median analyst target of $339. These ratings may help limit downside if revenue concerns stabilize. Average brokerage rating
• Positive Sentiment: Institutional activity was mixed but included substantial purchases, led by JPMorgan Chase adding nearly 5.9 million shares. Recent insider activity was also net positive, with three purchases versus one sale over six months, although these transactions are not necessarily tied to current fundamentals.
• Neutral Sentiment: Recent earnings-call coverage continues to examine Cencora’s quarterly performance, customer trends and outlook, but the available reports do not identify a new catalyst that would materially change the investment case. Earnings call analysis
• Negative Sentiment: Investors remain cautious after Cencora reduced its fiscal 2026 revenue-growth outlook to 4%–6%. Management cited lower wholesale acquisition prices and IRA-related reductions, faster brand conversions at a major mail-order customer, slower GLP-1 growth and customer losses.
• Negative Sentiment: Analysts have previously lowered several price targets following the outlook reset, reinforcing concerns that top-line pressure could persist even though adjusted earnings expectations, cash flow and share-repurchase support remain comparatively strong. Cencora share-movement analysis

Wall Street Analyst Weigh In

Several research analysts have weighed in on COR shares. Morgan Stanley increased their price target on shares of Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a report on Friday. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Evercore reiterated an “outperform” rating and set a $350.00 target price on shares of Cencora in a research note on Thursday, August 6th. Citigroup reissued a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $374.25.

Cencora Stock Performance

The stock’s 50-day simple moving average is $296.42 and its 200-day simple moving average is $313.81. The stock has a market cap of $62.48 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 1.87 and a beta of 0.57. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $4.00 earnings per share. Analysts forecast that Cencora, Inc. will post 17.84 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, August 14th. Cencora’s dividend payout ratio is presently 17.83%.

Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several hedge funds have recently bought and sold shares of the company. Westpac Banking Corp acquired a new position in shares of Cencora in the 2nd quarter valued at approximately $4,861,000. Sumitomo Life Insurance Co. bought a new stake in Cencora during the second quarter worth $518,000. William Blair Investment Management LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at $785,000. Korea Investment CORP bought a new position in Cencora in the second quarter valued at about $8,247,000. Finally, Ieq Capital LLC bought a new stake in shares of Cencora during the 2nd quarter valued at approximately $285,000. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.